On September 30, 2026, a narrative review titled "Peptides in urology and sexual medicine: clinical effectiveness, dosing, indications, and safety: a narrative review" was published in Sexual Medicine Reviews. The publication addresses peptides, including sermorelin, within the context of urology and sexual medicine. Sermorelin remains classified as an unapproved compound used only in research settings. This review is listed in PubMed under ID 42862021. The publication is described as a narrative review, a format that synthesizes existing literature on a topic rather than presenting new original trial data. No specific findings, outcomes, or safety data from the review have been detailed beyond its title and publication venue. Readers interested in the scope of this review should consult the full text through the journal or PubMed listing for complete context on what the authors examined. For general background on sermorelin, including its research status and classification, readers can consult the compound overview.
Sermorelin Featured in New Narrative Review on Peptides in Sexual Medicine
See the full sermorelin overview
Source: https://pubmed.ncbi.nlm.nih.gov/42862021/